保留腮腺全脑放疗与传统全脑放疗的多中心随机临床试验
这项多中心随机试验比较保留腮腺与传统全脑放疗对脑转移患者口干的影响,共56例随机、48例可分析。主要终点1个月口干评分未达统计学差异,但放疗结束时口干加重比例在保留腮腺组更低,且无边缘复发。
要点
- 保留腮腺全脑放疗未显著改善1个月口干主要终点。
- 放疗结束时口干加重比例保留腮腺组更低(22% vs 52%,P=.05)。
- 两组均未出现边缘复发,保留腮腺方案安全性可接受。
核心结论
- 不覆盖上颈段的保留腮腺全脑放疗是安全的,可能减少预期寿命有限患者的急性口干。
- 主要终点1个月口干评分未达显著差异,但放疗结束时的口干改善具有统计学意义。
研究设计与样本
- 多中心随机临床试验,2018至2021年入组3家学术中心接受全脑放疗(30-35 Gy/10-15次)的脑转移患者。
- 随机分为传统野组(下方覆盖C1-C2椎体、不前瞻性勾画腮腺)与保留腮腺野组(省略颈段覆盖、勾画腮腺并限制V20Gy≤25%)。
- 共56例随机,48例(每组24例)符合分析条件。
主要发现
- 传统组与保留腮腺组平均腮腺剂量分别为17 Gy与10 Gy。
- 1个月时平均口干评分分别为17与8(P=.06),≥15分增加比例分别为12%与16%(P=.56)。
- 放疗结束时≥15分增加比例传统组高于保留腮腺组(52% vs 22%,P=.05)。
- 腮腺V5Gy(P=.04)和V10Gy(P=.05)与放疗结束时口干相关。
- 多因素分析显示保留腮腺全脑放疗与放疗结束时口干改善相关(P=.04),但与1个月口干无关(P=.06)。
关键数值与推荐
- 全脑放疗剂量为30-35 Gy分10-15次,采用三维适形野。
- 保留腮腺野定义:省略颈段覆盖,勾画腮腺并限制V20Gy≤25%。
- 口干采用密歇根大学口干问卷评分(0-100,越高越差)。
- 主要终点为1个月口干评分,分析≥15分增加比例和模型估计平均评分。
- 次要终点为边缘复发(≤1 cm超出全脑放疗野)。
临床怎么用
- 对预期寿命有限的脑转移患者,可考虑采用保留腮腺全脑放疗以减轻急性口干。
- 实施时需省略上颈段覆盖并勾画腮腺,限制腮腺V20Gy≤25%。
- 需关注腮腺低剂量区(V5Gy、V10Gy)对急性口干的影响。
- 该方案未增加边缘复发风险,但需更大样本验证。
局限性
- 样本量较小(可分析48例),主要终点未达统计学显著。
- 随访时间较短,仅报告至6个月的口干数据。
- 仅纳入采用三维适形野的患者,结果可能不适用于调强放疗等技术。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Xerostomia (dry mouth) is common after conventional whole brain radiation therapy (WBRT) for brain metastases and is associated with parotid dose. No studies have reported whether parotid-sparing WBRT reduces this toxicity. We assessed whether parotid-sparing WBRT reduces xerostomia compared with conventional WBRT. METHODS AND MATERIALS: Patients receiving WBRT (30-35 Gy in 10-15 fractions) using 3-dimensional fields were enrolled at 3 academic centers from 2018 to 2021. Patients were randomized to conventional fields (covering C1-C2 vertebrae inferiorly without prospective delineation of parotids) versus parotid-sparing fields (omission of C-spine coverage; parotids delineated and V20Gy limited to 25%). Patients completed the University of Michigan Xerostomia Questionnaire (scored 0-100, higher = worse xerostomia) at baseline, within 5 days of WBRT completion (EndRT), 2 weeks, 1, 3, and 6 months. The primary endpoint was xerostomia score at 1 month (1M), analyzed as proportion with ≥15-point increase and as model-estimated mean xerostomia score. The secondary endpoint was marginal tumor relapse (≤1 cm outside WBRT fields). RESULTS: A total of 56 patients were randomized and 48 (24 in each arm) were eligible for analysis. Mean parotid dose was 17 versus 10 Gy with conventional versus parotid-sparing WBRT. At 1M, mean xerostomia score was 17 versus 8 (P = .06). The primary endpoint at 1M was not met; the proportion with ≥15-point increase in xerostomia score did not differ significantly between conventional versus parotid-sparing fields (12% vs 16%; P = .56). However, proportion with ≥15-point increase in xerostomia score at EndRT was higher with conventional versus parotid-sparing treatment (52% vs 22%; P = .05). Parotid V5Gy (P = .04) and V10Gy (P = .05) were associated with xerostomia at EndRT. On multivariable analysis, parotid-sparing WBRT was associated with improved xerostomia at EndRT (P = .04) but not at 1M (P = .06). There were no marginal relapses in either arm. CONCLUSIONS: Parotid sparing without coverage of upper cervical vertebra appears safe and potentially reduces acute xerostomia in patients with limited life expectancy receiving conventional WBRT.
引用
- Wang K, Deal AM, Shen CJ, et al. Parotid-Sparing Versus Conventional Whole Brain Radiation Therapy: A Multi-Institutional Randomized Clinical Trial. Int J Radiat Oncol Biol Phys. 2025. PMID: 41161645. doi:10.1016/j.ijrobp.2025.10.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。